Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Scholar Rock Holding ( (SRRK) ) has provided an announcement.
On January 12, 2026, Scholar Rock issued a corporate update outlining 2026 strategic priorities centered on securing U.S. and European regulatory approvals and commercial launch for apitegromab in children and adults with SMA, expanding development of apitegromab into infants under two years of age and FSHD, and advancing its broader anti-myostatin pipeline including subcutaneous apitegromab and SRK-439. The company reported an estimated $365 million in cash, cash equivalents and marketable securities as of December 31, 2025, providing runway into 2027, highlighted progress on remediation and capacity expansion at U.S. fill-finish manufacturers to underpin supply for apitegromab, and detailed 2025 milestones including major FDA and EMA regulatory steps, leadership restructuring to support its transition to a commercial-stage organization, and continued clinical execution across multiple trials that collectively strengthen its positioning as a potential leader in neuromuscular disease therapeutics.
The most recent analyst rating on (SRRK) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Scholar Rock Holding stock, see the SRRK Stock Forecast page.
Spark’s Take on SRRK Stock
According to Spark, TipRanks’ AI Analyst, SRRK is a Neutral.
Overall score reflects very weak current fundamentals (no revenue, large losses, and heavy cash burn) partially offset by constructive technical momentum and a mixed-but-manageable near-term outlook from the earnings call (cash runway into 2027 and strong trial results, tempered by FDA/third-party manufacturing compliance delays).
To see Spark’s full report on SRRK stock, click here.
More about Scholar Rock Holding
Scholar Rock (NASDAQ: SRRK) is a Cambridge, Massachusetts-based global biopharmaceutical company focused on rare, severe and debilitating neuromuscular diseases, particularly spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD), using a proprietary anti-myostatin platform to develop muscle-targeted therapies such as its lead candidate apitegromab and pipeline asset SRK-439.
Average Trading Volume: 2,003,680
Technical Sentiment Signal: Strong Buy
Current Market Cap: $4.25B
Learn more about SRRK stock on TipRanks’ Stock Analysis page.